Oxeladin

Oxeladin

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	R05DB09 (WHO)
Identifiers
IUPAC name 2-(2-diethylaminoethoxy)ethyl 2-ethyl-2-phenyl-butanoate
CAS Number	468-61-1 N
PubChem CID	4619
DrugBank	DB04822 Y
ChemSpider	4458 Y
UNII	SNC1080T5Y
KEGG	D08310 Y
ChEMBL	ChEMBL1500276 N
CompTox Dashboard (EPA)	DTXSID0048343
ECHA InfoCard	100.006.740
Chemical and physical data
Formula	C20H33NO3
Molar mass	335.488 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(OCCOCCN(CC)CC)C(c1ccccc1)(CC)CC
InChI InChI=1S/C20H33NO3/c1-5-20(6-2,18-12-10-9-11-13-18)19(22)24-17-16-23-15-14-21(7-3)8-4/h9-13H,5-8,14-17H2,1-4H3 Y Key:IQADUMSPOQKAAO-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Oxeladin is a cough suppressant. It is a highly potent and effective drug used to treat all types of cough of various etiologies. It is not related to opium or its derivatives, so treatment with oxeladin is free of risk of dependence or addiction. Oxeladin has none of the side effects (such as hypnosis, respiratory depression, tolerance, constipation and analgesia) which are present when common antitussives, such as codeine and its derivatives, are used. It may be used at every age, as well as in patients with heart disease, since it has a high level of safety and a great selectivity to act on the bulbar centre of cough.

Indications

Oxeladin is indicated in all types of cough. Besides its antitussive action, it helps to clear the respiratory tract, since it increases the quantity of secretion and thins bronchial secretion.

• Irritative cough
• Allergic cough
• Psychogenic cough
• Treatment of cough in patients with heart disease (it has no action upon the cardiovascular system)
• Infectious cough: tracheitis, bronchitis, pneumonia
• Treatment of cough in pre- and post-operative treatment for bronchoscopy

Contraindications

Although fetal malformations have not been reported, oxeladin should not be used during the first trimester of pregnancy. Oxeladin is contraindicated in patients with MAOI therapy.

Side effects

Rarely, some patients have reported rash, dizziness, sedation or mild digestive disturbances. These usually disappear on reducing the dosage or interrupting the treatment.

Addiction

Oxeladin differs from common antitussives that cause addiction (such as etilmorphin, codeine or its derivatives) in that there is no evidence of risk of addiction or dependence.

Composition and packaging

Oxeladin is available as drops, syrup and tablets, providing easier ways of management which will be chosen depending on the age and clinical stage.

Drops

Each 1ml (33 drops) contains oxeladin citrate 20 mg. The bottle contains 20ml of solution.

Syrup

Each 100ml contains oxeladin citrate 200 mg. The bottle contains 100ml of syrup.

Tablets

Each tablet contains oxeladin citrate 20 mg. The box contains 20 tablets in blister packs

Dosage

• Children 2-5yrs: 2.5ml-5ml (17 drops) every 4–6 hours
• Children 6-12 yrs: 10ml (33 drops), or 1 tablet, every 4–6 hours
• Children 12 yrs and over and adults: 15ml (50 drops), or 2 tablets, every 4–6 hours

Restrictions in use and availability

The Drug and Medical Technology Agency of Armenia rejected the registration of oxeladin in July 2000 since studies in Germany have shown potential carcinogenicity of the drug. (Reference: Communication to WHO, 9 August 2000.)